The Chikungunya virus is transmitted to humans via infected mosquitoes and causes large outbreaks with high attack rates. With outbreaks in Africa, America, Asia, Europe, and islands in the Indian and Pacific Oceans the Chikungunya virus is posing a growing risk to citizens and travelers in infected regions of the world. Still no vaccine or preventive drug is available and annual sales for an efficient vaccine are expected to exceed 300 Mio USD annually.
Themis' Chikungunya vaccine candidate already proved its excellent immunogenicity profile as well as its safety and tolerability in a phase I clinical trial. Results showing clear dose responses were published in the 'The Lancet Infectious Diseases' in 2015. The further clinical development is currently progressing well and market approval is expected within the next 2 to 3 years.